Altimmune Inc (NASDAQ:ALT) shares, rose in value on Thursday, March 27, with the stock price down by -0.36% to the previous day’s close as strong demand from buyers drove the stock to $5.57.
Actively observing the price movement in the last trading, the stock closed the session at $5.59, falling within a range of $5.45 and $5.63. The value of beta (5-year monthly) was 0.855. Referring to stock’s 52-week performance, its high was $11.16, and the low was $5.14. On the whole, ALT has fluctuated by -6.23% over the past month.
With the market capitalization of Altimmune Inc currently standing at about $428.97 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 500.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ALT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of ALT currently trading nearly -3.08% and -11.16% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.17, while the 7-day volatility ratio is showing 4.76% which for the 30-day chart, stands at 7.14%. Furthermore, Altimmune Inc (ALT)’s beta value is 0.83, and its average true range (ATR) is 0.38.
A comparison of Altimmune Inc (ALT) with its peers suggests the former has fared considerably weaker in the market. ALT showed an intraday change of -0.36% in last session, and over the past year, it shrunk by -34.70%%.
Data on historical trading for Altimmune Inc (NASDAQ:ALT) indicates that the trading volumes over the past 10 days have averaged 3.3 and over the past 3 months, they’ve averaged 2.52 million. According to company’s latest data on outstanding shares, there are 77.01 million shares outstanding.
Nearly 1.04% of Altimmune Inc’s shares belong to company insiders and institutional investors own 53.12% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 22.45 million shares as on 2025-03-14, resulting in a short ratio of 7.0. According to the data, the short interest in Altimmune Inc (ALT) stood at 2939.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 22.47 million. The stock has fallen by -22.75% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ALT stock heading into the next quarter.
